Ramdas Kumar, MD
Nephrology · Thousand Oaks, CANPI 1669631248
Payments from drug & device makers
Across 354 payments — averaging $37.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- AstraZeneca$2K
- Otsuka America Pharmaceutical, Inc.$712
- Bayer$554
- Novartis$407
- Vifor Pharma, Inc.$374
- plus $3K from 25 others
What the payments were for
- Consulting fees$3,28525%
- Food & beverage$9,91675%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 83 | $5,552 |
| AstraZeneca(2 entities) | 75 | $2,297 |
| Otsuka America Pharmaceutical, Inc. | 28 | $712 |
| Bayer | 20 | $554 |
| Novartis | 15 | $407 |
| Vifor Pharma, Inc. | 14 | $374 |
| GSK | 12 | $308 |
| Mallinckrodt Hospital Products Inc. | 10 | $277 |
| Novo Nordisk | 14 | $277 |
| Aurinia Pharma U.S., Inc. | 7 | $233 |
| Lilly USA, LLC | 14 | $221 |
| Boehringer Ingelheim | 9 | $217 |
| Akebia Therapeutics Inc | 4 | $198 |
| Mallinckrodt Enterprises LLC | 4 | $169 |
| Calliditas Therapeutics US Inc. | 7 | $158 |
| Amarin Pharma, Inc. | 2 | $149 |
| Johnson & Johnson | 5 | $149 |
| Qiagen, LLC | 1 | $145 |
| Daiichi Sankyo Inc. | 6 | $128 |
| AbbVie | 1 | $125 |
| Lexicon Pharmaceuticals, Inc. | 1 | $122 |
| Travere Therapeutics, Inc. | 4 | $96 |
| Sanofi | 4 | $92 |
| Fresenius USA Marketing, Inc. | 4 | $78 |
| Currax Pharmaceuticals LLC | 3 | $46 |
| Scpharmaceuticals Inc. | 2 | $44 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| Ardelyx, Inc. | 1 | $17 |
| OPKO Pharmaceuticals, LLC | 1 | $16 |
| Amicus Therapeutics, Inc. | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,220 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 196 | $164,948 |
| KerendiaFinerenone | 43 | $53,840 |
| VelphoroSucroferric Oxyhydroxide | 13 | $43,910 |
| JardianceEmpagliflozin | 43 | $28,627 |
| EntrestoSacubitril/Valsartan | 33 | $26,196 |
| VeltassaPatiromer Calcium Sorbitex | 23 | $25,980 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $17,715 |
| ProcritEpoetin Alfa | 17 | $16,201 |
| Sevelamer Carbonate | 35 | $13,318 |
| TradjentaLinagliptin | 12 | $5,987 |
| Valsartan | 72 | $3,700 |
| Nebivolol Hcl | 29 | $3,187 |
| Chlorthalidone | 161 | $2,496 |
| Bumetanide | 58 | $2,140 |
| Amlodipine Besylate | 229 | $2,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $2,297 | $182,662217 claims |
| BayerKerendia | $554 | $53,84043 claims |
| Fresenius USA Marketing, Inc.Velphoro | $78 | $43,91013 claims |
| Boehringer IngelheimJardiance, Tradjenta | $217 | $34,61455 claims |
| NovartisEntresto | $407 | $26,19633 claims |
| Johnson & JohnsonProcrit | $149 | $16,20117 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $13 | $3,70072 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.
Other nephrology in Thousand Oaks
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.